http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008540559-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024
filingDate 2006-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2008-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2008540559-A
titleOfInvention Glufosfamide combination therapy
abstract Administering glufosfamide alone or in combination with other chemotherapeutic agents is useful in the treatment of cancer. In one aspect, the cancer treatment method provided by the present invention comprises administering to a subject in need of treatment a therapeutically effective dose of glufosfamide in combination with doxorubicin (eg, adriamycin, doxyl, and Caelix). To include. In one embodiment, the method of treating cancer provided by the present invention comprises administering glufosfamide in combination with erlotinib (Tarceva ™).
priorityDate 2005-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448365594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7847
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23662274
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513138
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID598
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2942
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426079013
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419561789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19796026
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559217
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415824407
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413708594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559464
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419519950
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151115
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11077
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID33
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407319186
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415853116
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123596
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454269980
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505536
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123628
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71308134
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534036

Total number of triples: 54.